| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DLL1 |
| Uniprot No | O00548 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 22-543aa |
| 氨基酸序列 | SGVFELKLQEFVNKKGLLGNRNCCRGGAGPPPCACRTFFRVCLKHYQASV SPEPPCTYGSAVTPVLGVDSFSLPDGGGADSAFSNPIRFPFGFTWPGTFS LIIEALHTDSPDDLATENPERLISRLATQRHLTVGEEWSQDLHSSGRTDL KYSYRFVCDEHYYGEGCSVFCRPRDDAFGHFTCGERGEKVCNPGWKGPYC TEPICLPGCDEQHGFCDKPGECKCRVGWQGRYCDECIRYPGCLHGTCQQP WQCNCQEGWGGLFCNQDLNYCTHHKPCKNGATCTNTGQGSYTCSCRPGYT GATCELGIDECDPSPCKNGGSCTDLENSYSCTCPPGFYGKICELSAMTCA DGPCFNGGRCSDSPDGGYSCRCPVGYSGFNCEKKIDYCSSSPCSNGAKCV DLGDAYLCRCQAGFSGRHCDDNVDDCASSPCANGGTCRDGVNDFSCTCPP GYTGRNCSAPVSRCEHAPCHNGATCHERGHRYVCECARGYGGPNCQFLLP ELPPGPAVVDLTEKLEGQGGPF |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于DLL1重组蛋白的3篇参考文献示例(文献信息为虚构示例，仅供参考格式)：
1. **文献名称**：Structural and Functional Analysis of Recombinant DLL1 Protein in Notch Signaling
**作者**：Smith A, et al.
**摘要**：该研究通过大肠杆菌系统成功表达并纯化重组DLL1胞外域蛋白，解析了其与Notch受体结合的晶体结构，揭示其特异性激活Notch信号的关键表位。
2. **文献名称**：Recombinant DLL1-Fc Fusion Protein Enhances T-cell Differentiation in vitro
**作者**：Wang L, et al.
**摘要**：利用哺乳动物细胞表达系统制备DLL1-Fc融合蛋白，证实其可通过激活Notch通路促进体外T细胞分化，为免疫治疗提供潜在工具。
3. **文献名称**：Development of a DLL1-Based Recombinant Protein for Cancer Stem Cell Targeting
**作者**：Chen H, et al.
**摘要**：构建重组DLL1蛋白偶联纳米颗粒，靶向乳腺癌干细胞表面Notch受体，体内实验显示其显著抑制肿瘤生长并降低转移风险。
(注：以上文献为模拟内容，实际研究中请通过PubMed或学术数据库查询真实文献。)
**Background of DLL1 Recombinant Protein**
DLL1 (Delta-like 1) is a transmembrane ligand of the Notch signaling pathway, a highly conserved system critical for cell-cell communication, differentiation, and tissue development. As a member of the Delta/Serrate/LAG-2 (DSL) family, DLL1 binds to Notch receptors (e.g., NOTCH1-4) on adjacent cells, triggering proteolytic cleavage and release of the Notch intracellular domain (NICD). This initiates transcriptional regulation of target genes, influencing processes like stem cell maintenance, cell fate determination, and tissue homeostasis.
Recombinant DLL1 protein is engineered *in vitro* to mimic the functional extracellular domain of native DLL1. often produced in mammalian or insect cell systems to ensure proper post-translational modifications (e.g., glycosylation). It is purified for research or therapeutic applications, enabling controlled studies of Notch signaling without full transmembrane expression.
DLL1's role spans developmental biology, cancer, and immunology. In embryogenesis, it regulates neurogenesis, somitogenesis, and vascular development. Dysregulation of DLL1-Notch signaling is linked to cancers (e.g., leukemia, breast cancer) and immune disorders. For instance, DLL1 overexpression in tumors may drive angiogenesis or chemoresistance, while its inhibition can suppress tumor growth.
In regenerative medicine, recombinant DLL1 is used to manipulate stem cell differentiation *in vitro*, such as directing hematopoietic or neural progenitor cells. It also serves as a tool for drug screening, antibody development, and mechanistic studies of Notch-related diseases.
Despite its utility, challenges remain in balancing Notch activation/inhibition due to pathway complexity. Ongoing research focuses on optimizing DLL1-based therapies and understanding context-dependent signaling outcomes.
×
